Nothing says “end of summer” like high school football practice, apple cider, and Halloween decorations. Everyone packs up their sand chairs and boogie boards and heads back to the classroom, or workplace, whichever is most applicable. Here at MJH Life Sciences®, where education and events go hand-in-hand, our studios have been polished up all summer to bring a series of medical education programs for our physician audience. Titles such as NSCLC Insights, CKD Stakeholder Summit, and Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME, are all intended to help physicians improve their patients’ outcomes.
On the Industry Sciences side, MJH strives to contribute to these efforts in a different way. We inform and educate those professionals who research new compounds, investigate potential therapies in clinical trials, manufacture and distribute these drugs, and who also inform patients and healthcare professionals (HCPs) on the most appropriate ways to take advantage of
innovative drugs.
Here, in addition to events, Industry Sciences offers webcasts, digitally-enhanced “books” and magazines, videos, podcasts, and other forms of educational material for our audiences.
Some current topics that may have relevance to clinical trial professionals when peeking ahead to potential commercial viability, especially those developing hopeful advanced and curative treatments, include:
The American Medical Association reports that overall health spending was 18.3% of GDP in 2021 compared with 19.7% of GDP in 2020. That figure was down a bit, but still represents a hefty piece of the pie. Of this, 31.1% went to hospital care, 14.9% to physician services, and 8.9% to prescription drugs.
Of course with any large enterprise, complexities abound. This complexity—a constantly evolving and moving target—ensures that learning new information must take precedence for all decision-makers. Please take advantage of our many resources as you head back to work and educate yourself on all the latest issues, challenges, and strategic guidance impacting your decisions.
Thank you for reading.
Mike Hennessy Jr. is the president and CEO of Applied Clinical Trials' parent company, MJH Life Sciences®
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.